These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 79522)

  • 1. [Varying course of pancytopenia after busulfan treatment of chronic myelocytic leukemia (CML)].
    Krug K; Stenzel L
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1978; 105(2):181-7. PubMed ID: 79522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of busulfan-induced pancytopenia.
    Stuart JJ; Crocker DL; Roberts HR
    Arch Intern Med; 1976 Oct; 136(10):1181-3. PubMed ID: 1067785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [High-dose busulfan with subsequent bone marrow transplantation in poor-risk forms of leukemia].
    Urban C; Slavc I; Kaulfersch W; Teubl I
    Wien Klin Wochenschr; 1987 Mar; 99(5):144-9. PubMed ID: 3554777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Busulfan-induced sideroblastic anemia.
    Fernandez LA; Zayed E
    Am J Hematol; 1988 Jul; 28(3):199-200. PubMed ID: 3165601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chronic myeloid leukemia treated with busulfan. Clinical characteristics, prognostic factors, effect of treatment and survival in 82 cases].
    Larrain C; Cruz A; Codoceo V
    Rev Med Chil; 1984 Sep; 112(9):898-911. PubMed ID: 6598227
    [No Abstract]   [Full Text] [Related]  

  • 6. Chemotherapy of chronic myelocytic leukemia.
    Galton DA
    Semin Hematol; 1969 Oct; 6(4):323-43. PubMed ID: 4900650
    [No Abstract]   [Full Text] [Related]  

  • 7. [A trial for prolongation of chronic phase of chronic myeloid leukemia--maintenance of leukocyte counts within normal range with busulfan].
    Matsuo T; Tomonaga M; Kuriyama K; Jinnai I; Jubashi T; Nonaka H; Kohno T; Tsukasaki K; Atogami S; Itoyama T
    Rinsho Ketsueki; 1989 May; 30(5):625-30. PubMed ID: 2795875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic myeloid leukaemia and a myasthenic syndrome.
    Wohl MA; Wood JK
    Acta Haematol; 1979; 62(4):214-8. PubMed ID: 119414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytochemical variants of neutrophil leukocyte populations in chronic myelocytic leukaemia. A microspectrophotometric study of the change in the periodic acid-Schiff (PAS) reaction in blood and bone marrow neutrophils during busulfan treatment.
    Gahrton G; Brandt L; Franzén S; Nordén A
    Scand J Haematol; 1969; 6(6):365-72. PubMed ID: 4190430
    [No Abstract]   [Full Text] [Related]  

  • 10. [Indirubin in the treatment of chronic myelocytic leukemia (CML)--estimation of labelling index of bone marrow cells by 3H-TdR].
    You YC; Mi JX; Wan JH; Yang TY; Wang ZC; Qian LS
    Zhonghua Zhong Liu Za Zhi; 1987 Nov; 9(6):418-20. PubMed ID: 3482992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro drug sensitivity studies of CFUc in chronic myelocytic leukemia: I. Suicide indices and busulfan sensitivity determinations during the chronic phase.
    Preisler HD; Kirshner J
    Exp Hematol; 1983 Aug; 11(7):618-25. PubMed ID: 6576910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromosome changes in patients treated with "Myleran".
    Krajincanić B; Lazarov A; Zunić Z; Radojicić B
    Strahlentherapie; 1976 May; 151(5):459-62. PubMed ID: 1064182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Toxic effects of busulfan (myleran) in the treatment of chronic myeolid leukemia].
    Japp H
    Schweiz Med Wochenschr; 1974 Aug; 104(32):1115-9. PubMed ID: 4548568
    [No Abstract]   [Full Text] [Related]  

  • 14. Chronic granulocytic leukemia: long-term remission in a patient with familial sarcoidosis.
    Cheng DS; Kitahara M; Logan KH
    South Med J; 1979 Jun; 72(6):645-7. PubMed ID: 287201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of allogeneic bone marrow transplant in chronic myeloid leukaemia following conditioning with busulfan and cyclophosphamide.
    Saikia TK; Advani SH; Parikh PM; Bapna A; Somjee S; Mukhopadhyay A; Gopal R; Nair CN
    J Assoc Physicians India; 1999 Aug; 47(8):770-3. PubMed ID: 10778619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bullous pyoderma gangrenosum in association with myeloid leukaemia.
    Cramers M
    Acta Derm Venereol; 1976; 56(4):311-2. PubMed ID: 60030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of chronic myeloid leukemia with repeated single doses of busulfan.
    Sullivan JR; Hurley TH; Bolton JH
    Cancer Treat Rep; 1977; 61(1):43-5. PubMed ID: 266418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pulmonary fibrosis after busulfan therapy].
    Jandl H; Franke A; Albrecht G
    Z Gesamte Inn Med; 1975 Dec; 30(24):799-801. PubMed ID: 1062873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apoptosis and proliferation (PCNA labelling) in CML--a comparative immunohistological study on bone marrow biopsies following interferon and busulfan therapy.
    Thiele J; Zirbes TK; Lorenzen J; Kvasnicka HM; Dresbach S; Manich B; Leder LD; Niederle N; Diehl V; Fischer R
    J Pathol; 1997 Mar; 181(3):316-22. PubMed ID: 9155719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic bone marrow transplantation in high-risk myeloid disorders using busulfan, cytosine arabinoside and cyclophosphamide (BAC).
    Ratanatharathorn V; Karanes C; Lum LG; Uberti J; Dan ME; de Planque MM; Schultz KR; Cronin S; Leisz MC; Mohamed A
    Bone Marrow Transplant; 1992 Jan; 9(1):49-55. PubMed ID: 1543949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.